Pfizer is one of the world's largest pharma companies and has a diversified portfolio of drugs for treating a variety of conditions. Its top drugs include its Comirnaty COVID-19 vaccine, its Paxlovid COVID-19 oral treatment and its Prevnar pneumococcal vaccine. Hardy says recent reports that Pfizer is considering divesting its hospital drugs business are good news and could help Pfizer generate additional funding to focus on its high-growth, core businesses. Activist investor Starboard creates a certain degree of uncertainty, but Hardy says Starboard could also help unlock value. CFRA has a "buy" rating and $30 price target for PFE stock, which closed at $25.56 on Dec. 3.